| Journal | PLOS mental health |
| Study Type | Clinical Study |
| Population | Human participants |
This real-world evidence from the UK’s regulated medical cannabis program provides crucial clinical data on cannabis effectiveness for primary insomnia, addressing a condition where conventional treatments often fall short. The 124-patient registry analysis offers practical insights into how cannabis-based medicinal products perform in actual clinical practice rather than controlled trial conditions.
This case series analyzed 124 patients with primary insomnia from the UK Medical Cannabis Registry, tracking sleep quality, anxiety, and quality of life measures over 18 months. Patients showed significant improvement in Single-Item Sleep Quality Scale scores from baseline (2.66) to 1 month (5.67), with sustained benefits maintained through follow-up periods. The study also assessed anxiety (GAD-7) and quality of life (EQ-5D-5L) measures alongside adverse event monitoring using standardized CTCAE criteria. While promising, the observational design lacks placebo controls and may be subject to selection bias typical of registry studies.
“I find registry data particularly valuable because it reflects how cannabis actually works in clinical practice rather than artificial trial conditions. These sustained sleep improvements align with what I observe clinically, though the lack of control group limits definitive conclusions about cannabis-specific effects versus natural improvement or placebo response.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
How effective are cannabis-based medicinal products for treating insomnia?
This UK registry study found significant improvements in sleep quality scores from baseline (2.66) to 1 month (5.67) that were sustained through 18 months of follow-up. Additionally, patients experienced improvements in anxiety and overall quality of life measures, suggesting cannabis-based medicines may offer meaningful clinical benefits for insomnia patients.
How long does it take to see improvements in sleep quality with medical cannabis?
The study demonstrated statistically significant improvements in sleep quality as early as 1 month after starting cannabis-based medicinal products. These improvements were maintained consistently at 3, 6, 12, and 18-month follow-up assessments, indicating both rapid onset and sustained therapeutic effects.
What are the safety concerns with using medical cannabis for insomnia?
The study assessed adverse events according to standardized criteria (CTCAE version 4.0) in 124 participants with primary insomnia. While the complete adverse event profile wasn’t detailed in the provided summary, the fact that patients continued treatment for up to 18 months suggests a generally acceptable safety profile in this real-world clinical setting.
Yes, the study measured anxiety using the GAD-7 scale and found improvements alongside sleep quality measures. This suggests that cannabis-based medicinal products may provide dual benefits for patients with insomnia who also experience anxiety, which commonly co-occur in clinical practice.
How does this study compare to other insomnia treatments?
While this registry study doesn’t directly compare cannabis-based products to other treatments, it acknowledges that current insomnia treatments have limitations, affecting approximately 10% of adults globally. The sustained improvements over 18 months and concurrent benefits in anxiety and quality of life measures suggest cannabis-based medicines may address some gaps in current therapeutic options.
